Protein targets of inflammatory serine proteases and cardiovascular disease

Serine proteases are a key component of the inflammatory response as they are discharged from activated leukocytes and mast cells or generated through the coagulation cascade. Their enzymatic activity plays a major role in the body's defense mechanisms but it has also an impact on vascular homeostasis and tissue remodeling. Here we focus on the biological role of serine proteases in the context of cardiovascular disease and their mechanism(s) of action in determining specific vascular and tissue phenotypes. Protease-activated receptors (PARs) mediate serine protease effects; however, these proteases also exert a number of biological activities independent of PARs as they target specific protein substrates implicated in vascular remodeling and the development of cardiovascular disease thus controlling their activities. In this review both PAR-dependent and -independent mechanisms of action of serine proteases are discussed for their relevance to vascular homeostasis and structural/functional alterations of the cardiovascular system. The elucidation of these mechanisms will lead to a better understanding of the molecular forces that control vascular and tissue homeostasis and to effective preventative and therapeutic approaches.

[1]  L. Iacoviello,et al.  Cathepsin G--induced release of PAI-1 in the culture medium of endothelial cells: a new thrombogenic role for polymorphonuclear leukocytes? , 1993, The Journal of laboratory and clinical medicine.

[2]  Stefan Offermanns,et al.  Mammalian G proteins and their cell type specific functions. , 2005, Physiological reviews.

[3]  T. Chao,et al.  The endogenous immune response modulates the course of IgA-immune complex mediated nephropathy. , 2006, Kidney international.

[4]  B. Clarke,et al.  Neutrophil activation detected by increased neutrophil elastase activity in type 1 (insulin-dependent) diabetes mellitus. , 1989, Diabetes research.

[5]  S. Schwartz,et al.  Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[6]  H. Neurath,et al.  Mast cell proteases. , 1981, Methods in enzymology.

[7]  Xiaomin Wang,et al.  Leukocyte elastase induces epithelial apoptosis: role of mitochondial permeability changes and Akt. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[8]  E. Diamandis,et al.  Functional Roles of Human Kallikrein-related Peptidases* , 2009, The Journal of Biological Chemistry.

[9]  R. Weiss,et al.  The mitogenic effect of thrombin in vascular smooth muscle cells is largely due to basic fibroblast growth factor. , 1993, The Journal of biological chemistry.

[10]  Paula Clancy,et al.  Association Between Osteopontin and Human Abdominal Aortic Aneurysm , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[11]  C. Orosz,et al.  Regulation of endothelial VCAM-1 expression in murine cardiac grafts. Roles for TNF and IL4. , 1995, The American journal of pathology.

[12]  P. Libby,et al.  CC Chemokine Receptor-1 Activates Intimal Smooth Muscle-Like Cells in Graft Arterial Disease , 2009, Circulation.

[13]  G. Hayman,et al.  Thrombin modulates vectorial secretion of extracellular matrix proteins in cultured endothelial cells. , 1997, The American journal of physiology.

[14]  Thomas A Luger,et al.  Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. , 2005, Endocrine reviews.

[15]  S. Verma,et al.  Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein , 2002, Circulation.

[16]  N. Fukazawa,et al.  Cathepsin g is required for sustained inflammation and tissue injury after reperfusion of ischemic kidneys. , 2007, The American journal of pathology.

[17]  Nagadhara Dronadula,et al.  Thrombin induces expression of FGF-2 via activation of PI3K-Akt-Fra-1 signaling axis leading to DNA synthesis and motility in vascular smooth muscle cells. , 2006, American journal of physiology. Cell physiology.

[18]  J. Fallon,et al.  Tissue Factor in the Pathogenesis of Atherosclerosis , 1997, Thrombosis and Haemostasis.

[19]  P. Densen,et al.  Mechanisms of contraction induced by human leukocytes in normal and atherosclerotic arteries. , 1991, Circulation research.

[20]  Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species. , 2001, The Biochemical journal.

[21]  A. Ariel,et al.  IL-2 induces T cell adherence to extracellular matrix: inhibition of adherence and migration by IL-2 peptides generated by leukocyte elastase. , 1998, Journal of immunology.

[22]  M. Hollenberg,et al.  Detection of functional receptors for the proteinase-activated-receptor-2-activating polypeptide, SLIGRL-NH2, in rat vascular and gastric smooth muscle. , 1995, Canadian journal of physiology and pharmacology.

[23]  D. Granger,et al.  Modulation of the Inflammatory Response in Cardiovascular Disease , 2004, Hypertension.

[24]  Jingwu Z. Zhang,et al.  Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways in rheumatoid arthritis. , 2009, Arthritis and rheumatism.

[25]  L. Schack,et al.  Osteopontin Is Cleaved at Multiple Sites Close to Its Integrin-binding Motifs in Milk and Is a Novel Substrate for Plasmin and Cathepsin D* , 2010, The Journal of Biological Chemistry.

[26]  C. Derian,et al.  Blocking the Protease-Activated Receptor 1-4 Heterodimer in Platelet-Mediated Thrombosis , 2006, Circulation.

[27]  R. Anderson,et al.  Neutrophil lysosomal degradation of human CRP: CRP-derived peptides modulate neutrophil function. , 1988, Clinical and experimental immunology.

[28]  C. Feistritzer,et al.  Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. , 2005, Blood.

[29]  TatsuhikoSudo,et al.  Involvement of Apoptosis Signal-Regulating Kinase-1 on Angiotensin II-Induced Monocyte Chemoattractant Protein-1 Expression , 2004 .

[30]  Wuyuan Lu,et al.  Multiple pathways of amino terminal processing produce two truncated variants of RANTES/CCL5 , 2005, Journal of leukocyte biology.

[31]  E. Antunes,et al.  The plasma and tissue kininogen-kallikrein-kinin system: role in the cardiovascular system. , 2005, Current medicinal chemistry. Cardiovascular and hematological agents.

[32]  M. Simon,et al.  Defective platelet activation in G alpha(q)-deficient mice. , 1997, Nature.

[33]  L. Dell’Italia,et al.  Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases. , 2002, Current opinion in cardiology.

[34]  R. Crystal,et al.  Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. , 1992, The Journal of clinical investigation.

[35]  R. Guldberg,et al.  Inactivation of the Osteopontin Gene Enhances Vascular Calcification of Matrix Gla Protein–deficient Mice , 2002, The Journal of experimental medicine.

[36]  G. Downey,et al.  Neutrophil-mediated epithelial injury during transmigration: role of elastase. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[37]  A. Loewy,et al.  An Osteopontin–NADPH Oxidase Signaling Cascade Promotes Pro–Matrix Metalloproteinase 9 Activation in Aortic Mesenchymal Cells , 2006, Circulation research.

[38]  D. Ku,et al.  Receptor Mechanism of Thrombin‐Induced Endothelium‐Dependent and Endothelium‐Independent Coronary Vascular Effects in Dogs , 1993, Journal of cardiovascular pharmacology.

[39]  J. Griffin,et al.  Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. , 2004, Blood.

[40]  D. Remick,et al.  Neutralization of Groα and macrophage inflammatory protein-2 attenuates renal ischemia/reperfusion injury , 2001 .

[41]  M. Stack,et al.  Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). , 1994, The Journal of biological chemistry.

[42]  J. Heemskerk,et al.  Synergistic Effect of Thrombin on Collagen-Induced Platelet Procoagulant Activity Is Mediated Through Protease-Activated Receptor-1 , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[43]  A. Galloway,et al.  Mechanisms of c-reactive protein up-regulation in arterialized vein grafts. , 2006, Surgery.

[44]  S. Coughlin,et al.  Protease‐activated receptors in hemostasis, thrombosis and vascular biology , 2005, Journal of thrombosis and haemostasis : JTH.

[45]  J. Fischer,et al.  Cholesterol Enhances Thrombin-Induced Release of Fibroblast Growth Factor-2 in Human Vascular Smooth Muscle Cells , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[46]  H. Kantarjian,et al.  Biology of platelet-derived growth factor and its involvement in disease. , 2006, Mayo Clinic proceedings.

[47]  D. Carden,et al.  Neutrophil elastase promotes lung microvascular injury and proteolysis of endothelial cadherins. , 1998, American journal of physiology. Heart and circulatory physiology.

[48]  L. Schwartz,et al.  The fibrinogenolytic activity of purified tryptase from human lung mast cells. , 1985, Journal of immunology.

[49]  K. Mann,et al.  What is all that thrombin for? , 2003, Journal of thrombosis and haemostasis : JTH.

[50]  J. Wallace,et al.  Protease-activated receptors in inflammation, neuronal signaling and pain. , 2001, Trends in pharmacological sciences.

[51]  A. Sommer,et al.  Human basic fibroblast growth factor gene encodes four polypeptides: three initiate translation from non-AUG codons. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[52]  M. Hollenberg,et al.  Proteinases, proteinase-activated receptors (PARs) and the pathophysiology of cancer and diseases of the cardiovascular, musculoskeletal, nervous and gastrointestinal systems , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

[53]  A. Prats,et al.  Alternative translation of human fibroblast growth factor 2 mRNA occurs by internal entry of ribosomes , 1995, Molecular and cellular biology.

[54]  A. Schmaier,et al.  High molecular weight kininogen binds to platelets by its heavy and light chains and when bound has altered susceptibility to kallikrein cleavage. , 1992, Blood.

[55]  A. Agarwal,et al.  PAR1 Is a Matrix Metalloprotease-1 Receptor that Promotes Invasion and Tumorigenesis of Breast Cancer Cells , 2005, Cell.

[56]  A. Newby,et al.  Molecular mechanisms in intimal hyperplasia , 2000, The Journal of pathology.

[57]  D. Katsaros,et al.  Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. , 2003, Cancer research.

[58]  S. Devaraj,et al.  C-Reactive Protein Decreases Prostacyclin Release From Human Aortic Endothelial Cells , 2003, Circulation.

[59]  J. Taipale,et al.  Human Mast Cell Chymase and Leukocyte Elastase Release Latent Transforming Growth Factor-β1 from the Extracellular Matrix of Cultured Human Epithelial and Endothelial Cells (*) , 1995, The Journal of Biological Chemistry.

[60]  Q. Zen,et al.  Effect of human C-reactive protein on chemokine and chemotactic factor-induced neutrophil chemotaxis and signaling. , 1998, Journal of immunology.

[61]  E. Diamandis,et al.  Proteinase-activated Receptors, Targets for Kallikrein Signaling* , 2006, Journal of Biological Chemistry.

[62]  A. Galloway,et al.  Matrix metalloproteinase expression in vein grafts: role of inflammatory mediators and extracellular signal-regulated kinases-1 and -2. , 2006, American journal of physiology. Heart and circulatory physiology.

[63]  M. Okazaki,et al.  Osteopontin-derived peptide SVVYGLR induces angiogenesis in vivo. , 2004, Dental materials journal.

[64]  M. Hollenberg,et al.  International Union of Pharmacology. XXVIII. Proteinase-Activated Receptors , 2002, Pharmacological Reviews.

[65]  S. Akira,et al.  Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. , 1999, Immunity.

[66]  A. Kuliopulos,et al.  Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[67]  T. Kôno,et al.  Insulin-like effects of trypsin on fat cells. Localization of the metabolic steps and the cellular site affected by the enzyme. , 1971, The Journal of biological chemistry.

[68]  C. Turck,et al.  Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface , 1994, Nature.

[69]  S. Schwartz,et al.  Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[70]  Thiennu H. Vu,et al.  Thrombin receptor expression in normal and atherosclerotic human arteries. , 1992, The Journal of clinical investigation.

[71]  M. Runge,et al.  The Role of Secondary Growth Factor Production in Thrombin-lnduced Proliferation of Vascular Smooth Muscle Cells , 1998, Seminars in thrombosis and hemostasis.

[72]  M. Benezra,et al.  Thrombin-induced release of active basic fibroblast growth factor-heparan sulfate complexes from subendothelial extracellular matrix. , 1993, Blood.

[73]  C. Boudier,et al.  The elastolytic activity of cathepsin G: an ex vivo study with dermal elastin. , 1991, American journal of respiratory cell and molecular biology.

[74]  J. Trejo,et al.  Caveolae are required for protease-selective signaling by protease-activated receptor–1 , 2009, Proceedings of the National Academy of Sciences.

[75]  M. Hollenberg,et al.  Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more , 2008, British journal of pharmacology.

[76]  James T. Willerson,et al.  Modulation of C-Reactive Protein–Mediated Monocyte Chemoattractant Protein-1 Induction in Human Endothelial Cells by Anti-Atherosclerosis Drugs , 2001 .

[77]  M. Denis,et al.  Release of interleukin-8, interleukin-6, and colony-stimulating factors by upper airway epithelial cells: implications for cystic fibrosis. , 1993, American journal of respiratory cell and molecular biology.

[78]  N. Yamamoto,et al.  Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. , 2003, The Journal of clinical investigation.

[79]  S. Marcus,et al.  Activation of progelatinase A (MMP‐2) by neutrophil elastase, cathepsin G, and proteinase‐3: A role for inflammatory cells in tumor invasion and angiogenesis , 2001, Journal of cellular physiology.

[80]  B. Payrastre,et al.  A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. , 1999, Blood.

[81]  M. D'Andrea,et al.  Characterization of Thrombin-Induced Leukocyte Rolling and Adherence: A Potential Proinflammatory Role for Proteinase-Activated Receptor-41 , 2002, The Journal of Immunology.

[82]  A. Galloway,et al.  Thrombin cleaves the high molecular weight forms of basic fibroblast growth factor (FGF-2): a novel mechanism for the control of FGF-2 and thrombin activity , 2008, Oncogene.

[83]  D. Sheppard,et al.  Osteopontin N-terminal Domain Contains a Cryptic Adhesive Sequence Recognized by α9β1 Integrin* , 1996, The Journal of Biological Chemistry.

[84]  H. Kanaide,et al.  Role of protease-activated receptors in the vascular system. , 2003, Journal of atherosclerosis and thrombosis.

[85]  E. Van Obberghen-Schilling,et al.  Distinct signals via Rho GTPases and Src drive shape changes by thrombin and sphingosine-1-phosphate in endothelial cells. , 2002, Journal of cell science.

[86]  S. Weiss Tissue destruction by neutrophils. , 1989, The New England journal of medicine.

[87]  Y. Matsui,et al.  Osteopontin Deficiency Attenuates Atherosclerosis in Female Apolipoprotein E–Deficient Mice , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[88]  S. Akira,et al.  Defective NK cell activity and Th1 response in IL-18-deficient mice. , 1998, Immunity.

[89]  A. A. Taylor,et al.  Inflammation in the course of early myocardial ischemia , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[90]  K. Fujikawa,et al.  The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. , 1986, The Journal of biological chemistry.

[91]  H. Pass,et al.  Correlation between plasma osteopontin levels and aortic valve calcification: potential insights into the pathogenesis of aortic valve calcification and stenosis. , 2009, The Journal of thoracic and cardiovascular surgery.

[92]  L. Joosten,et al.  An IFN-γ-Independent Proinflammatory Role of IL-18 in Murine Streptococcal Cell Wall Arthritis , 2000, The Journal of Immunology.

[93]  R. Stockley,et al.  Lung lavage fluid from patients with alpha 1-proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profile. , 1987, Clinical science.

[94]  Z. Fayad,et al.  Associations between plasma osteopontin levels and the severities of coronary and aortic atherosclerosis. , 2010, Atherosclerosis.

[95]  K. Aoshiba,et al.  C-reactive protein products generated by neutrophil elastase promote neutrophil apoptosis. , 2006, Archives of medical research.

[96]  Carlos López-Otín,et al.  A genomic analysis of rat proteases and protease inhibitors. , 2004, Genome research.

[97]  R. Busuttil,et al.  The inhibition of neutrophil elastase ameliorates mouse liver damage due to ischemia and reperfusion , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[98]  G. D. Hunter,et al.  Proteinase-activated receptors. , 2001, Pharmacological reviews.

[99]  C. Alpers,et al.  Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis. , 1994, Kidney international.

[100]  O. Kwon,et al.  Pro-tumour necrosis factor cleavage enzyme in macrophage membrane/particulate. , 1993, Immunology.

[101]  J. Verhoef,et al.  Inactivation of recombinant human tumor necrosis factor-alpha by proteolytic enzymes released from stimulated human neutrophils. , 1991, Journal of immunology.

[102]  S. Yoshitake,et al.  Antibody to thrombin receptor inhibits neointimal smooth muscle cell accumulation without causing inhibition of platelet aggregation or altering hemostatic parameters after angioplasty in rat. , 1998, Circulation research.

[103]  J. Abraham,et al.  Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor. , 2000, Circulation research.

[104]  P. Mak,et al.  Effects of elastase and cathepsin G on the levels of membrane and soluble TNFα , 2005, Biological chemistry.

[105]  Richard T. Lee,et al.  Macrophages and atherosclerotic plaque stability , 1996, Current opinion in lipidology.

[106]  P. Cuatrecasas Properties of the insulin receptor of isolated fat cell membranes. , 1971, The Journal of biological chemistry.

[107]  C. Ince,et al.  Recombinant activated protein C treatment improves tissue perfusion and oxygenation in septic patients measured by near-infrared spectroscopy , 2009, Critical care.

[108]  H. Davis,et al.  Regulation of endothelial cell gap formation and barrier dysfunction: Role of myosin light chain phosphorylation , 1995, Journal of cellular physiology.

[109]  A. Galloway,et al.  Lack of ERK activation and cell migration in FGF‐2‐deficient endothelial cells , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[110]  M. Schork,et al.  Reduction of the Extent of Ischemic Myocardial Injury by Neutrophil Depletion in the Dog , 1983, Circulation.

[111]  E. Edelman,et al.  Increased Thrombosis After Arterial Injury in Human C-Reactive Protein–Transgenic Mice , 2003, Circulation.

[112]  A. Leger,et al.  Protease-Activated Receptors in Cardiovascular Diseases , 2006, Circulation.

[113]  L. Matrisian,et al.  Osteopontin, a Novel Substrate for Matrix Metalloproteinase-3 (Stromelysin-1) and Matrix Metalloproteinase-7 (Matrilysin)* , 2001, The Journal of Biological Chemistry.

[114]  C. Owen,et al.  The cell biology of leukocyte‐mediated proteolysis , 1999, Journal of leukocyte biology.

[115]  Wuyuan Lu,et al.  N‐terminal proteolytic processing by cathepsin G converts RANTES/CCL5 and related analogs into a truncated 4‐68 variant , 2006, Journal of leukocyte biology.

[116]  S. Coughlin,et al.  Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. , 1993, The Journal of clinical investigation.

[117]  S. Roman-Roman,et al.  In Vitro Processing of Human Tumor Necrosis Factor-α (*) , 1995, The Journal of Biological Chemistry.

[118]  A. Galloway,et al.  Basic fibroblast growth factor (FGF‐2): The high molecular weight forms come of age , 2007, Journal of cellular biochemistry.

[119]  J. Aschner,et al.  Thrombin receptor activating peptides induce Ca2+ mobilization, barrier dysfunction, prostaglandin synthesis, and platelet‐derived growth factor mRNA expression in cultured endothelium , 1993, Journal of cellular physiology.

[120]  E. Diamandis,et al.  The emerging roles of human tissue kallikreins in cancer , 2004, Nature Reviews Cancer.

[121]  B. Rauch,et al.  Thrombin- and Factor Xa–Induced DNA Synthesis Is Mediated by Transactivation of Fibroblast Growth Factor Receptor-1 in Human Vascular Smooth Muscle Cells , 2004, Circulation research.

[122]  D. Sheppard,et al.  The Integrin α9β1 Binds to a Novel Recognition Sequence (SVVYGLR) in the Thrombin-cleaved Amino-terminal Fragment of Osteopontin* , 1999, The Journal of Biological Chemistry.

[123]  C. Kahn,et al.  Tryptic activation of the insulin receptor. Proteolytic truncation of the alpha-subunit releases the beta-subunit from inhibitory control. , 1988, The Journal of biological chemistry.

[124]  C. Murry,et al.  Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. , 1998, The American journal of pathology.

[125]  E. Diamandis,et al.  Human tissue kallikreins: physiologic roles and applications in cancer. , 2004, Molecular cancer research : MCR.

[126]  W. Aird,et al.  Thrombin and Phenotypic Modulation of the Endothelium , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[127]  P. Libby,et al.  Neutrophil Elastase in Human Atherosclerotic Plaques: Production by Macrophages , 2003, Circulation.

[128]  E. Diamandis,et al.  Kallikrein-related peptidases: proteolysis and signaling in cancer, the new frontier , 2010, Biological chemistry.

[129]  Sridevi Devaraj,et al.  Demonstration That C-Reactive Protein Decreases eNOS Expression and Bioactivity in Human Aortic Endothelial Cells , 2002, Circulation.

[130]  A. Wiedlocha,et al.  Functional diversity of FGF-2 isoforms by intracellular sorting. , 2006, BioEssays : news and reviews in molecular, cellular and developmental biology.

[131]  N. Itoh,et al.  Evolution of the Fgf and Fgfr gene families. , 2004, Trends in genetics : TIG.

[132]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[133]  D. Ku,et al.  Expression of thrombin receptors in human atherosclerotic coronary arteries leads to an exaggerated vasoconstrictory response in vitro. , 1997, Journal of cardiovascular pharmacology.

[134]  D. Kunz,et al.  Selective proteolytic cleavage of IL-2 receptor and IL-6 receptor ligand binding chains by neutrophil-derived serine proteases at foci of inflammation. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[135]  V. Wheaton,et al.  Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. , 1992, The Journal of biological chemistry.

[136]  Harry,et al.  C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. , 1993, Blood.

[137]  L. Liaw,et al.  Osteopontin: A Multifunctional Molecule Regulating Chronic Inflammation and Vascular Disease , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[138]  C. Geczy,et al.  C-reactive Protein : Relationship with Age, Sex, and Hormone Replacement Treatment and Lipopolysaccharide Potentiate Monocyte Tissue Factor Induction by Γ Interferon- Interferon-␥ and Lipopolysaccharide Potentiate Monocyte Tissue Factor Induction by C-reactive Protein Relationship with Age, Sex, and , 2022 .

[139]  R. Bizios,et al.  Thrombin‐Induced Alterations in Endothelial Permeability a , 1986, Annals of the New York Academy of Sciences.

[140]  W. Ruf,et al.  Science review: Role of coagulation protease cascades in sepsis , 2002, Critical care.

[141]  M. Schaefer,et al.  Requirement of an Intermediate Gene Expression for Biphasic ERK1/2 Activation in Thrombin-stimulated Vascular Smooth Muscle Cells* , 2008, Journal of Biological Chemistry.

[142]  Hyuk-Jae Chang,et al.  Development of a point-of-care assay system for high-sensitivity C-reactive protein in whole blood. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[143]  D. Agrawal,et al.  Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft intimal hyperplasia , 2006, Immunology and cell biology.

[144]  K. Kinnally,et al.  Neutrophil Cathepsin G Promotes Detachment-induced Cardiomyocyte Apoptosis via a Protease-activated Receptor-independent Mechanism* , 2003, Journal of Biological Chemistry.

[145]  N. Tsopanoglou,et al.  On the Mechanism of Thrombin-induced Angiogenesis , 1999, The Journal of Biological Chemistry.

[146]  M. Hollenberg,et al.  Proteinase‐activated receptor‐4: evaluation of tethered ligand‐derived peptides as probes for receptor function and as inflammatory agonists in vivo , 2004, British journal of pharmacology.

[147]  A. Burlingame,et al.  HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[148]  L. Williams,et al.  Thrombin stimulates c-sis gene expression in microvascular endothelial cells. , 1986, The Journal of biological chemistry.

[149]  Reuven Reich,et al.  Thrombin receptor overexpression in malignant and physiological invasion processes , 1998, Nature Medicine.

[150]  C. Valeri,et al.  Postischemic renal injury is mediated by neutrophils and leukotrienes. , 1989, The American journal of physiology.

[151]  D. Remick,et al.  Neutralization of Gro alpha and macrophage inflammatory protein-2 attenuates renal ischemia/reperfusion injury. , 2001, The American journal of pathology.

[152]  Steven Patierno,et al.  Tissue factor, thrombin, and cancer. , 2003, Chest.

[153]  J. Baguet,et al.  Cathepsin G is associated with atheroma formation in human carotid artery , 2004, Journal of hypertension.

[154]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[155]  Shokei Kim,et al.  Involvement of Apoptosis Signal-Regulating Kinase-1 on Angiotensin II-Induced Monocyte Chemoattractant Protein-1 Expression , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[156]  P. Scuderi Suppression of human leukocyte tumor necrosis factor secretion by the serine protease inhibitor p-toluenesulfonyl-L-arginine methyl ester (TAME). , 1989, Journal of immunology.

[157]  G. Lozanski,et al.  Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. , 1992, Cytokine.

[158]  R. Marthan,et al.  Tryptase and agonists of PAR-2 induce the proliferation of human airway smooth muscle cells. , 2001, Journal of applied physiology.

[159]  Gunnar Pejler,et al.  Mast cell proteases: multifaceted regulators of inflammatory disease. , 2010, Blood.

[160]  E. Bramucci,et al.  Tissue-factor antigen and activity in human coronary atherosclerotic plaques , 1997, The Lancet.

[161]  B. Rauch,et al.  Platelet-Derived Growth Factor-BB–Induced Human Smooth Muscle Cell Proliferation Depends on Basic FGF Release and FGFR-1 Activation , 2005, Circulation research.

[162]  A. Galloway,et al.  Mechanical endothelial damage results in basic fibroblast growth factor-mediated activation of extracellular signal-regulated kinases. , 1999, Surgery.

[163]  C. Lucchinetti,et al.  Activity of a newly identified serine protease in CNS demyelination. , 2002, Brain : a journal of neurology.

[164]  A. Cucina,et al.  Autocrine production of basic fibroblast growth factor translated from novel synthesized mRNA mediates thrombin‐induced mitogenesis in smooth muscle cells , 2002, Cell biochemistry and function.

[165]  R. Falk,et al.  Novel effects of neutrophil-derived proteinase 3 and elastase on the vascular endothelium involve in vivo cleavage of NF-kappaB and proapoptotic changes in JNK, ERK, and p38 MAPK signaling pathways. , 2002, Journal of the American Society of Nephrology : JASN.

[166]  D. Spandidos,et al.  Genetic diversity of RANTES gene promoter and susceptibility to coronary artery disease and restenosis after percutaneous coronary intervention. , 2009, Thrombosis research.

[167]  K. Valerie,et al.  Novel Mode for Neutrophil Protease Cathepsin G-Mediated Signaling: Membrane Shedding of Epidermal Growth Factor Is Required for Cardiomyocyte Anoikis , 2008, Circulation research.

[168]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[169]  J. Chen,et al.  Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. , 1996, The Journal of biological chemistry.

[170]  M. Gnecchi,et al.  Genetic therapies for cardiovascular diseases. , 2005, Trends in molecular medicine.

[171]  C. Nathan,et al.  Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor. Comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils. , 1991, The Journal of biological chemistry.

[172]  R. Kettritz,et al.  Apoptosis of endothelial cells induced by the neutrophil serine proteases proteinase 3 and elastase. , 1996, The American journal of pathology.

[173]  N. Ozer,et al.  Plasma soluble osteopontin concentrations are increased in patients with rheumatic mitral stenosis and associated with the severity of mitral valve calcium. , 2006, The American journal of cardiology.

[174]  K. Nadeau,et al.  The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand. , 1997, The Journal of clinical investigation.

[175]  S. Devaraj,et al.  C-Reactive Protein Increases Plasminogen Activator Inhibitor-1 Expression and Activity in Human Aortic Endothelial Cells: Implications for the Metabolic Syndrome and Atherothrombosis , 2003, Circulation.

[176]  M. Lark,et al.  Comparison of the proteoglycanolytic activities of human leukocyte elastase and human cathepsin G in vitro and in vivo. , 1993, Connective tissue research.

[177]  Reiko Ohmori,et al.  High plasma levels of osteopontin in patients with restenosis after percutaneous coronary intervention. , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[178]  N. Tsopanoglou,et al.  Role of thrombin in angiogenesis and tumor progression. , 2004, Seminars in thrombosis and hemostasis.

[179]  V. Wheaton,et al.  Domains specifying thrombin–receptor interaction , 1991, Nature.

[180]  M. Mäyränpää,et al.  Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves. , 2006, European heart journal.

[181]  G. D. De Meyer,et al.  Role of polymorphonuclear leukocytes in collar-induced intimal thickening in the rabbit carotid artery. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[182]  C. López-Otín,et al.  A genomic view of the complexity of mammalian proteolytic systems. , 2005, Biochemical Society transactions.

[183]  T. Suganami,et al.  A Paracrine Loop Between Adipocytes and Macrophages Aggravates Inflammatory Changes: Role of Free Fatty Acids and Tumor Necrosis Factor α , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[184]  A. Kozubík,et al.  Molecular pathology of the fibroblast growth factor family , 2009, Human mutation.

[185]  M. Peppelenbosch,et al.  Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. , 2008, Trends in molecular medicine.

[186]  R. Abboud,et al.  Effect of smoking on plasma neutrophil elastase levels. , 1986, The Journal of laboratory and clinical medicine.

[187]  E. Milbrandt,et al.  Evidence-based Medicine Journal Club Ebm Journal Club Section Editor: a Disheartening Story: Aprotinin in Cardiac Surgery , 2022 .

[188]  Moses Rodriguez,et al.  Targeting kallikrein 6‐proteolysis attenuates CNS inflammatory disease , 2004, The FASEB Journal.

[189]  J. Schlessinger Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[190]  C. Orosz,et al.  Regulation of endothelial VCAM-1 expression in murine cardiac grafts. Expression of allograft endothelial VCAM-1 can be manipulated with antagonist of IFN-alpha or IL-4 and is not required for allograft rejection. , 1995, The American journal of pathology.

[191]  Reiko Ohmori,et al.  Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. , 2003, Atherosclerosis.

[192]  M. LeMasurier,et al.  Substrate-Assisted Catalysis of the PAR1 Thrombin Receptor , 2000, The Journal of Biological Chemistry.